ArticleThe American journal of pathology1995
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 199 citations in OpenAlex.
- A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2010Trial
- Malignant mesothelioma of the tunica vaginalis testis: A case report.Oncology letters · 2026Article
- Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.Non-coding RNA · 2023Article
- The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas.Journal of cancer metastasis and treatment · 2023Article
- Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library.Genome medicine · 2022Article
- Biological basis for novel mesothelioma therapies.British journal of cancer · 2021Review
- Immunotherapy in malignant pleural mesothelioma: a review of literature data.Translational lung cancer research · 2021Review
- Wilms' Tumor 1 (WT1): The Vaccine for Cancer.Journal of immunotherapy and precision oncology · 2020Review
- Fibrin Deposit on the Peritoneal Surface Serves as a Niche for Cancer Expansion in Carcinomatosis Patients.Neoplasia (New York, N.Y.) · 2019Article
- Article
- The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms).Critical reviews in toxicology · 2016Review
- Prognostic significance of WT1 expression in soft tissue sarcoma.World journal of surgical oncology · 2014Article
- Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities.Genes, chromosomes & cancer · 2014Article
- A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.Blood · 2014Article
- The pleural mesothelium in development and disease.Frontiers in physiology · 2014Article
- Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Cancer immunology, immunotherapy : CII · 2011Review
- LRRN4 and UPK3B are markers of primary mesothelial cells.PloS one · 2011Article
- Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.Diagnostic pathology · 2010Article
- [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].Medizinische Klinik (Munich, Germany : 1983) · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The distinction between malignant mesothelioma and other neoplastic processes involving the pleura is difficult, partly due to the lack of specific markers expressed on mesothelioma. Because of evidence suggesting that the Wilms' tumor susceptibility gene (WT1), unlike other tumor suppressor genes, is restricted mostly to mesenchymally derived tissues, we hypothesized that the WT1 gene products could serve as a potential marker for mesothelioma. The expression of WT1 mRNA was analyzed in 19 malignant mesothelioma cell lines and 9 tumors and compared with the expression of WT1 in 10 non-small cell lung cancer lines and 9 lung cancer specimens. WT1 mRNA was detectable by Northern analysis in 16 of 19 mesothelioma cell lines and in 5 of 8 malignant mesothelioma tumors. In contrast, WT1 mRNA was not detected by Northern analysis in non-small cell lung cancer lines or carcinomas. Immunoprecipitation with an anti-WT1 monoclonal antibody showed that a 52- to 54-kd protein was present in 4 mesothelioma cell lines. Immunostaining with this antibody localized the WT1 protein to the nucleus in two mesothelioma lines and in 20 of 21 mesothelioma tumors examined. This distinctive pattern of nuclear immunoreactivity was absent in 26 non-mesothelioma tumors involving the lung, including 20 non-small cell lung carcinomas. The detection of WT1 mRNA or protein may thus provide a specific molecular or immunohistochemical marker for differentiation of mesothelioma from other pleural tumors, in particular, adenocarcinoma.
Indexed as
Identifiers
7856747PMC1869867W1862483413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.